Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonia | 5 | 2025 | 61 | 2.980 |
Why?
|
| Ethanol | 4 | 2026 | 224 | 2.790 |
Why?
|
| Lung | 6 | 2026 | 492 | 2.520 |
Why?
|
| Pneumonia, Bacterial | 4 | 2025 | 24 | 2.280 |
Why?
|
| Immunomodulation | 2 | 2026 | 17 | 1.930 |
Why?
|
| Klebsiella Infections | 3 | 2025 | 11 | 1.770 |
Why?
|
| Klebsiella pneumoniae | 3 | 2025 | 26 | 1.760 |
Why?
|
| Cannabinoids | 2 | 2026 | 73 | 1.760 |
Why?
|
| Macrophages | 4 | 2026 | 529 | 1.170 |
Why?
|
| Receptor, Cannabinoid, CB1 | 2 | 2026 | 41 | 1.090 |
Why?
|
| Receptor, Cannabinoid, CB2 | 2 | 2026 | 38 | 1.080 |
Why?
|
| Lung Diseases | 2 | 2024 | 63 | 0.990 |
Why?
|
| Macrophages, Alveolar | 1 | 2026 | 34 | 0.970 |
Why?
|
| Cytokines | 7 | 2026 | 678 | 0.870 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2020 | 367 | 0.850 |
Why?
|
| Mice, Inbred C57BL | 6 | 2026 | 1869 | 0.810 |
Why?
|
| Environmental Monitoring | 1 | 2024 | 230 | 0.740 |
Why?
|
| Papillomavirus Infections | 4 | 2020 | 376 | 0.740 |
Why?
|
| Complex Mixtures | 1 | 2021 | 9 | 0.710 |
Why?
|
| Mice | 9 | 2026 | 6644 | 0.690 |
Why?
|
| Plague | 3 | 2015 | 25 | 0.670 |
Why?
|
| Yersinia pestis | 3 | 2015 | 35 | 0.660 |
Why?
|
| Calcium | 2 | 2021 | 491 | 0.610 |
Why?
|
| Cervix Uteri | 2 | 2018 | 48 | 0.600 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2018 | 20 | 0.580 |
Why?
|
| HMGB1 Protein | 1 | 2018 | 30 | 0.570 |
Why?
|
| HIV-1 | 3 | 2015 | 755 | 0.500 |
Why?
|
| Uterine Cervical Dysplasia | 4 | 2020 | 43 | 0.480 |
Why?
|
| Animals | 10 | 2026 | 16992 | 0.470 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2015 | 10 | 0.460 |
Why?
|
| Inflammation | 4 | 2026 | 758 | 0.440 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 75 | 0.440 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 2015 | 17 | 0.420 |
Why?
|
| Papillomaviridae | 3 | 2020 | 142 | 0.420 |
Why?
|
| Macrophage Activation | 2 | 2026 | 61 | 0.410 |
Why?
|
| Lipopolysaccharides | 2 | 2026 | 239 | 0.400 |
Why?
|
| Disease Models, Animal | 3 | 2025 | 1596 | 0.390 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2024 | 55 | 0.380 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2011 | 279 | 0.370 |
Why?
|
| Interferon Type I | 1 | 2011 | 18 | 0.350 |
Why?
|
| Thymus Gland | 1 | 2011 | 76 | 0.340 |
Why?
|
| Specimen Handling | 3 | 2020 | 63 | 0.330 |
Why?
|
| Cell Line | 4 | 2026 | 1410 | 0.320 |
Why?
|
| Flavoring Agents | 3 | 2025 | 22 | 0.310 |
Why?
|
| Male | 6 | 2026 | 23409 | 0.310 |
Why?
|
| Vaginal Smears | 2 | 2020 | 63 | 0.300 |
Why?
|
| Humans | 17 | 2026 | 43102 | 0.280 |
Why?
|
| Female | 10 | 2026 | 24698 | 0.270 |
Why?
|
| North Carolina | 4 | 2023 | 127 | 0.270 |
Why?
|
| Cell Polarity | 1 | 2026 | 57 | 0.240 |
Why?
|
| Receptors, Cannabinoid | 1 | 2025 | 31 | 0.230 |
Why?
|
| Nicotine | 2 | 2026 | 302 | 0.220 |
Why?
|
| Air Pollution | 1 | 2024 | 87 | 0.200 |
Why?
|
| Vagina | 2 | 2020 | 89 | 0.190 |
Why?
|
| Dendritic Cells | 2 | 2015 | 132 | 0.180 |
Why?
|
| Internship and Residency | 1 | 2023 | 146 | 0.180 |
Why?
|
| Environmental Exposure | 1 | 2024 | 256 | 0.180 |
Why?
|
| Cell Survival | 2 | 2025 | 945 | 0.170 |
Why?
|
| Chemotaxis | 1 | 2021 | 68 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2022 | 259 | 0.170 |
Why?
|
| Zebrafish | 1 | 2022 | 146 | 0.160 |
Why?
|
| Respiratory Mucosa | 1 | 2020 | 41 | 0.160 |
Why?
|
| Interleukin-6 | 1 | 2021 | 165 | 0.160 |
Why?
|
| DNA, Viral | 2 | 2020 | 311 | 0.160 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 37 | 0.160 |
Why?
|
| Cytoplasm | 1 | 2020 | 154 | 0.160 |
Why?
|
| Interferon-gamma | 1 | 2021 | 269 | 0.160 |
Why?
|
| Urinalysis | 1 | 2020 | 34 | 0.160 |
Why?
|
| Calcium Signaling | 1 | 2020 | 107 | 0.160 |
Why?
|
| Patient Preference | 1 | 2020 | 60 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 384 | 0.150 |
Why?
|
| Herpesvirus 4, Human | 1 | 2018 | 36 | 0.150 |
Why?
|
| HIV Infections | 3 | 2023 | 2586 | 0.140 |
Why?
|
| Disease Progression | 2 | 2018 | 667 | 0.140 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 45 | 0.140 |
Why?
|
| Gene Expression | 1 | 2021 | 701 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 497 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2024 | 719 | 0.130 |
Why?
|
| Epithelial Cells | 1 | 2020 | 434 | 0.130 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2018 | 174 | 0.130 |
Why?
|
| Signal Transduction | 2 | 2024 | 2157 | 0.120 |
Why?
|
| Oxidative Stress | 1 | 2021 | 1003 | 0.110 |
Why?
|
| Early Detection of Cancer | 4 | 2020 | 449 | 0.110 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2015 | 59 | 0.110 |
Why?
|
| Aged | 4 | 2020 | 8214 | 0.110 |
Why?
|
| Middle Aged | 5 | 2020 | 12222 | 0.100 |
Why?
|
| Neutrophil Infiltration | 1 | 2013 | 28 | 0.100 |
Why?
|
| United States | 1 | 2024 | 5205 | 0.100 |
Why?
|
| Adult | 5 | 2020 | 13872 | 0.090 |
Why?
|
| Neutrophils | 1 | 2013 | 145 | 0.090 |
Why?
|
| Lymphocyte Depletion | 1 | 2011 | 14 | 0.090 |
Why?
|
| Organ Culture Techniques | 1 | 2011 | 101 | 0.090 |
Why?
|
| Herpesvirus 8, Human | 1 | 2010 | 25 | 0.080 |
Why?
|
| Colposcopy | 2 | 2020 | 14 | 0.080 |
Why?
|
| Virus Attachment | 1 | 2009 | 4 | 0.080 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2009 | 7 | 0.080 |
Why?
|
| Virus Internalization | 1 | 2009 | 36 | 0.080 |
Why?
|
| Receptors, CXCR4 | 1 | 2009 | 74 | 0.070 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 186 | 0.070 |
Why?
|
| Peripheral Nervous System | 1 | 2025 | 14 | 0.060 |
Why?
|
| Phagocytosis | 1 | 2025 | 86 | 0.050 |
Why?
|
| Pentamidine | 1 | 2023 | 11 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2025 | 152 | 0.050 |
Why?
|
| Interferon-alpha | 2 | 2015 | 43 | 0.050 |
Why?
|
| Sensation | 1 | 2022 | 36 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2025 | 532 | 0.050 |
Why?
|
| Cultural Diversity | 1 | 2023 | 193 | 0.040 |
Why?
|
| Perception | 1 | 2022 | 215 | 0.040 |
Why?
|
| Mentha | 1 | 2020 | 2 | 0.040 |
Why?
|
| Self-Examination | 1 | 2020 | 9 | 0.040 |
Why?
|
| Biopsy | 1 | 2020 | 177 | 0.040 |
Why?
|
| Mycoplasma genitalium | 1 | 2018 | 3 | 0.040 |
Why?
|
| Trichomonas Vaginitis | 1 | 2018 | 5 | 0.040 |
Why?
|
| Mycoplasma Infections | 1 | 2018 | 6 | 0.040 |
Why?
|
| Trichomonas vaginalis | 1 | 2018 | 9 | 0.040 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2018 | 16 | 0.040 |
Why?
|
| Postal Service | 1 | 2018 | 13 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 440 | 0.040 |
Why?
|
| Gonorrhea | 1 | 2018 | 24 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 455 | 0.040 |
Why?
|
| Chlamydia trachomatis | 1 | 2018 | 70 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 611 | 0.040 |
Why?
|
| Genotype | 1 | 2020 | 800 | 0.030 |
Why?
|
| Self Care | 1 | 2018 | 175 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2018 | 200 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 1081 | 0.030 |
Why?
|
| Biological Warfare Agents | 1 | 2015 | 4 | 0.030 |
Why?
|
| Mass Screening | 1 | 2020 | 541 | 0.030 |
Why?
|
| Virulence | 1 | 2015 | 246 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 423 | 0.030 |
Why?
|
| Apoptosis | 1 | 2020 | 1568 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2010 | 9 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2010 | 39 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 127 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2010 | 224 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 1621 | 0.020 |
Why?
|